Commentary|Videos|December 18, 2024
Factors That Influence Treatment Decisions in Later-Line CML
Author(s)Javier Pinilla, MD, PhD, Talha Badar, MBBS, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.
Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.
Advertisement
Advertisement
Trending on OncLive
1
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
2
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
3
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
4
FDA Accepts NDA for Varegacestat in Desmoid Tumors
5